16Jan 2019

CURRENT STATUS OF HIV VACCINATION STRATEGY AND ITS IMPLICATION ON A DEVELOPING COUNTRY LIKE INDIA- A MINI-REVIEW.

  • Virus Research Laboratory, National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Department of Endocrinology and Metabolism, IPGMER & SSKM Hospital, Kolkata, India.
  • Department of Medicine, IPGMER & SSKM Hospital, Kolkata, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

At a time when numerous infectious diseases are kept under control with worldwide vaccination endeavors, the human immunodeficiency infection (HIV), identified in 1984, is still infecting millions around the world. From 1990 to 2017 the number of individuals living with HIV ascended from below 8 million to more than 36.9 million. Since the start of the HIV scourge, the infection has claimed more than 34 million lives. While antiretroviral medicines have definitely enhanced life expectancy and quality of life for individuals living with HIV, preventing the occurrence of HIV infection is as yet the essential objective, particularly for the low-income nations that are hardest hit and can't bear the cost of prolonged medications. Many years of effort have been spent, towards developing a low cost, powerful and safe HIV vaccine yet till now nothing substantial has come up. India with its immense populace of HIV positive patients is also taking a functioning part in this procedure. This review hereby provides a concise story of the currently adopted strategies involved in developing an effective HIV vaccine and also about the role played by India in this global effort.

  1. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384:1005-70.2.
  2. Global Update on HIV Treatment. World Health Organization 2018.
  3. The Gap Report. Joint United Nations Programme on HIV/AIDS 2014.
  4. Fact Sheet on HIV-2017. Global statistics. 2018.
  5. Daniel MD et al.?Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.Science 258: 1938-1941, 1992
  6. Baba TW et al.?Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.Science 267: 1820-1825, 1995
  7. Pinto LA et al.?HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients.AIDS 13: 335-339, 2002
  8. Kran AMB et al.?HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc 4x).AIDS 18: 1875-1883, 2004
  9. Barouch DH et al.?Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.Nature 415: 335-339, 2002
  10. Boyer JD et al.?Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.J Infect Dis 181: 476-483, 2000
  11. Schnell MJ et al.?Recombinant rabies virus as potential live-viral vaccines for HIV-1.ProcNatlAcadSci U S A 97: 3544-3549, 2000
  12. Hansen SG et al.?Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.Nature, early online publication, doi:10.1038/nature10003, May 2011
  13. Zhang H et al.?Human immunodeficiency virus type 1 Gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding Gag.J Virol 78: 10249-10257, 2004
  14. Ensoli B et al.?Candidate HIV-1 tat vaccine development: from basic science to clinical trials.AIDS 20(18):2245-2261, 2006
  15. Ensoli B et al.?Therapeutic immunization with HIV-1 tat reduces immune activation and loss of regulatory T-Cells and improves immune function in subjects on HAART.PLoS ONE 5(11): e13540. doi:10.1371/journal.pone.0013540, 2010
  16. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191:654?665. [PubMed: 15688278]
  17. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661?1671. [PubMed: 17109337]
  18. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996; 173:340?348. [PubMed: 8568294]
  19. Haynes BF, Verkoczy L, Kelsoe G. Redemption of autoreactive B cells. ProcNatlAcadSci U S A. 2014; 111:9022?9023. [PubMed: 24920593]
  20. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005; 191:666?677. [PubMed: 15688279]
  21. Tongo M, Burgers WA. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses. 2014; 6:3968?3990. [PubMed: 25341662]
  22. Ministry of Public Health?Thai AIDS Vaccine Evaluation Group. 2011. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29:4285?92
  23. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209?20
  24. Kayeyi N, Fylkesnes K, Michelo C, Makasa M, Sand?y I. Decline in HIV prevalence among young women in Zambia: National-level estimates of trends mask geographical and socio-demographic differences. PLoS One 2012; 7:e33652.
  25. Sekar R, Amudhan M, Sivashankar M, Veeran R, Jayachandran C, Mythreyee M. Declining trend of HIV infection among the rural population of South India ? A comparison of HIV prevalence in high risk and low risk groups. J Infect 2011; 63:91-2.
  26. Sekar R, Amudhan M, Sivashankar M, Mythreyee M. Recent trends in HIV prevalence in a remote setting of southern India: Insights into arranging HIV control policies. J Infect DevCtries 2013; 7:838-43.
  27. Excler JL. AIDS vaccine development: perspectives, challenges and hopes.?Indian J Med Res2005 Apr; 121: 568-81.
  28. Ohja VP, Pradhan BK.?The macroeconomic and sectoral impacts of HIV and AIDS in India: a CGE study. New Delhi; National Council of Applied Economic Research, National AIDS Control Organization, United Nations Development Programme: 2006.
  29. Sahni AK, Prasad VV, Seth P. Genomic diversity of human immunodeficiency virus type-1 in India.?Int J STD AIDS2002; 13: 115-8esani A. Coutinho L. AIDS vaccine trials in India: ethical benchmarks and unanswered questions.?Indian J Med Ethics?2007; 4: 2-3.
  30. Garrison C.?Intellectual property rights and vaccines in developing countries. Background paper for WHO workshop 2004 Apr 19-20; Geneva.
  31. Gadkari D A, Moore D, Sheppard H W, Kulkarni SS, Mehendale SM, Bollinger RC. Transmission of genetically diverse strains of HIV-1 in Pune, India.?Indian J Med Res1998 Jan; 107: 1-9.
  32. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384:258-71.
  33. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013;382:1525-33.
  34. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966-71.
  35. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. 2013. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J. Infect. Dis. 207:1195?205.

[Aroni Chatterjee, Hiya Ghosh, S Pain and Agnibha Maiti. (2019); CURRENT STATUS OF HIV VACCINATION STRATEGY AND ITS IMPLICATION ON A DEVELOPING COUNTRY LIKE INDIA- A MINI-REVIEW. Int. J. of Adv. Res. 7 (Jan). 983-988] (ISSN 2320-5407). www.journalijar.com

Agnibha Maiti
Department of Medicine, IPGMER & SSKM Hospital, Kolkata, India.

DOI:

Article DOI: 10.21474/IJAR01/8411      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8411

Download Full Paper

Download PDF No. of Downloads: 13 | No. of Views: 71